Skip to main content
Erschienen in: International Journal of Hematology 5/2010

01.06.2010 | Rapid Communication

High frequency of MEFV gene mutations in patients with myeloid neoplasm

verfasst von: Cagatay Oktenli, Ozkan Sayan, Serkan Celik, Alev A. Erikci, Yusuf Tunca, Hakan M. Terekeci, Elcin Erkuvan Umur, Yavuz S. Sanisoglu, Deniz Torun, Fatih Tangi, Burak Sahan, Selim Nalbant

Erschienen in: International Journal of Hematology | Ausgabe 5/2010

Einloggen, um Zugang zu erhalten

Abstract

We aimed to investigate the rate of MEFV, the gene mutated in familial Mediterranean fever, mutations in patients with myeloid neoplasm and to determine if known mutations of MEFV cause a tendency for myeloid neoplasms. The frequency of the five most common MEFV gene mutations (M694V, M680I, V726A, E148Q and M694I) was determined in 26 patients with myeloid neoplasm. We identified 1 homozygous (E148Q/E148Q), 1 compound heterozygous (M694V/E148Q) and 5 heterozygous MEFV gene mutations; none had their own and/or family history compatible with familial Mediterranean fever. The mean overall mutation rate was 0.269. We found a high frequency of carriers in patients with myelodysplastic syndrome (66.6%), polycythemia vera (33.3%) and acute myeloid leukemia (28.6%). However, there was no MEFV gene mutation in patients with chronic myeloid leukemia. In conclusion, this study reports for the first time a possibly high prevalence of MEFV gene mutations in patients with myeloid neoplasm, especially myelodysplastic syndrome, polycythemia vera and acute myeloid leukemia. Our findings could open new perspectives for MEFV gene mutations in myeloid neoplasms and its association with tumor promotion. Further research is needed to determine the actual role of MEFV gene mutations in these malignancies.
Literatur
1.
Zurück zum Zitat Musabak U, Sengul A, Oktenli C, Pay S, Yesilova Z, Kenar L, et al. Does immune activation continue during an attack-free period in familial Mediterranean fever? Clin Exp Immunol. 2004;138:526–33.CrossRefPubMed Musabak U, Sengul A, Oktenli C, Pay S, Yesilova Z, Kenar L, et al. Does immune activation continue during an attack-free period in familial Mediterranean fever? Clin Exp Immunol. 2004;138:526–33.CrossRefPubMed
2.
Zurück zum Zitat Terekeci HM, Oktenli C, Ozgurtas T, Nalbant S, Top C, Celik S, et al. Increased asymmetric dimethylarginine levels in young men with familial Mediterranean fever (FMF): is it early evidence of interaction between inflammation and endothelial dysfunction in FMF? J Rheumatol. 2008;35:2024–9.PubMed Terekeci HM, Oktenli C, Ozgurtas T, Nalbant S, Top C, Celik S, et al. Increased asymmetric dimethylarginine levels in young men with familial Mediterranean fever (FMF): is it early evidence of interaction between inflammation and endothelial dysfunction in FMF? J Rheumatol. 2008;35:2024–9.PubMed
3.
Zurück zum Zitat Terekeci HM, Ulusoy ER, Kucukarslan NM, Nalbant S, Oktenli C. Familial Mediterranean fever attacks do not alter functional and morphologic tissue Doppler echocardiographic parameters. Rheumatol Int. 2008;28:1239–43.CrossRefPubMed Terekeci HM, Ulusoy ER, Kucukarslan NM, Nalbant S, Oktenli C. Familial Mediterranean fever attacks do not alter functional and morphologic tissue Doppler echocardiographic parameters. Rheumatol Int. 2008;28:1239–43.CrossRefPubMed
4.
Zurück zum Zitat The French FMF. Consortium: a candidate gene for familial Mediterranean fever. Nat Genet. 1997;17:25–31.CrossRef The French FMF. Consortium: a candidate gene for familial Mediterranean fever. Nat Genet. 1997;17:25–31.CrossRef
5.
Zurück zum Zitat The International FMF. Consortium: ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell. 1997;90:797–807.CrossRef The International FMF. Consortium: ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell. 1997;90:797–807.CrossRef
6.
Zurück zum Zitat Guz G, Kanbay M, Ozturk MA. Current perspectives on familial Mediterranean fever. Curr Opin Infect Dis. 2009;22:309–15.CrossRefPubMed Guz G, Kanbay M, Ozturk MA. Current perspectives on familial Mediterranean fever. Curr Opin Infect Dis. 2009;22:309–15.CrossRefPubMed
7.
Zurück zum Zitat Touitou I. The spectrum of familial Mediterranean fever (FMF) mutations. Eur J Hum Genet. 2001;9:473–83.CrossRefPubMed Touitou I. The spectrum of familial Mediterranean fever (FMF) mutations. Eur J Hum Genet. 2001;9:473–83.CrossRefPubMed
8.
Zurück zum Zitat Centola M, Wood G, Frucht DM, Galon J, Aringer M, Farrell C, et al. The gene for familial Mediterranean fever, MEFV, is expressed in early leukocyte development and is regulated in response to inflammatory mediators. Blood. 2000;95:3223–31.PubMed Centola M, Wood G, Frucht DM, Galon J, Aringer M, Farrell C, et al. The gene for familial Mediterranean fever, MEFV, is expressed in early leukocyte development and is regulated in response to inflammatory mediators. Blood. 2000;95:3223–31.PubMed
9.
Zurück zum Zitat Grateau G. Clinical and genetic aspects of the hereditary periodic fever syndromes. Rheumatology. 2004;43:410–5.CrossRefPubMed Grateau G. Clinical and genetic aspects of the hereditary periodic fever syndromes. Rheumatology. 2004;43:410–5.CrossRefPubMed
10.
Zurück zum Zitat Koc B, Oktenli C, Bulucu F, Karadurmus N, Sanisoglu SY, Gul D. The rate of pyrin mutations in critically ill patients with systemic inflammatory response syndrome and sepsis: a pilot study. J Rheumatol. 2007;34:2070–5.PubMed Koc B, Oktenli C, Bulucu F, Karadurmus N, Sanisoglu SY, Gul D. The rate of pyrin mutations in critically ill patients with systemic inflammatory response syndrome and sepsis: a pilot study. J Rheumatol. 2007;34:2070–5.PubMed
11.
Zurück zum Zitat Stehlik C, Reed JC. The PYRIN connection: novel players in innate immunity and inflammation. J Exp Med. 2004;200:551–8.CrossRefPubMed Stehlik C, Reed JC. The PYRIN connection: novel players in innate immunity and inflammation. J Exp Med. 2004;200:551–8.CrossRefPubMed
12.
Zurück zum Zitat Chae JJ, Komarow HD, Cheng J, Wood G, Raben N, Liu PP, et al. Targeted disruption of pyrin, the FMF protein, causes heightened sensitivity to endotoxin and a defect in macrophage apoptosis. Mol Cell. 2003;11:591–604.CrossRefPubMed Chae JJ, Komarow HD, Cheng J, Wood G, Raben N, Liu PP, et al. Targeted disruption of pyrin, the FMF protein, causes heightened sensitivity to endotoxin and a defect in macrophage apoptosis. Mol Cell. 2003;11:591–604.CrossRefPubMed
13.
Zurück zum Zitat Dowds TA, Masumoto J, Chen FF, Ogura Y, Inohara N, Nunez G. Regulation of cryopyrin/Pypaf1 signaling by pyrin, the familial Mediterranean fever gene product. Biochem Biophys Res Commun. 2003;302:575–80.CrossRefPubMed Dowds TA, Masumoto J, Chen FF, Ogura Y, Inohara N, Nunez G. Regulation of cryopyrin/Pypaf1 signaling by pyrin, the familial Mediterranean fever gene product. Biochem Biophys Res Commun. 2003;302:575–80.CrossRefPubMed
14.
Zurück zum Zitat Gumucio DL, Diaz A, Schaner P, Richards N, Babcock C, Schaller M, et al. Fire and ICE: the role of pyrin domain containing proteins in inflammation and apoptosis. Clin Exp Rheumatol. 2002;20:S45–53.PubMed Gumucio DL, Diaz A, Schaner P, Richards N, Babcock C, Schaller M, et al. Fire and ICE: the role of pyrin domain containing proteins in inflammation and apoptosis. Clin Exp Rheumatol. 2002;20:S45–53.PubMed
15.
Zurück zum Zitat Manji GA, Wang L, Geddes BJ, Brown M, Merriam S, Al-Garawi A, et al. PYPAF1, a PYRIN-containing Apaf1-like protein that assembles with ASC and regulates activation of NF-kappa B. J Biol Chem. 2002;277:11570–5.CrossRefPubMed Manji GA, Wang L, Geddes BJ, Brown M, Merriam S, Al-Garawi A, et al. PYPAF1, a PYRIN-containing Apaf1-like protein that assembles with ASC and regulates activation of NF-kappa B. J Biol Chem. 2002;277:11570–5.CrossRefPubMed
16.
Zurück zum Zitat Stehlik C, Krajewska M, Welsh K, Krajewski S, Godzik A, Reed JC. The PAAD/PYRIN-only protein POP1/ASC2 is a modulator of ASC-mediated NF-κB and pro-caspase-1 regulation. Biochem J. 2003;373:101–13.CrossRefPubMed Stehlik C, Krajewska M, Welsh K, Krajewski S, Godzik A, Reed JC. The PAAD/PYRIN-only protein POP1/ASC2 is a modulator of ASC-mediated NF-κB and pro-caspase-1 regulation. Biochem J. 2003;373:101–13.CrossRefPubMed
17.
Zurück zum Zitat Stehlik C, Fiorentino L, Dorfleutner A, Bruey JM, Ariza EM, Sagara J, et al. The PAAD/PYRIN-family protein ASC is a dual regulator of a conserved step in nuclear factor kappaB activation pathways. J Exp Med. 2002;196:1605–15.CrossRefPubMed Stehlik C, Fiorentino L, Dorfleutner A, Bruey JM, Ariza EM, Sagara J, et al. The PAAD/PYRIN-family protein ASC is a dual regulator of a conserved step in nuclear factor kappaB activation pathways. J Exp Med. 2002;196:1605–15.CrossRefPubMed
18.
Zurück zum Zitat Keutgens A, Robert I, Viatour P, Chariot A. Deregulated NF-kB activity in haematological malignancies. Biochem Pharmacol. 2006;72:1069–80.CrossRefPubMed Keutgens A, Robert I, Viatour P, Chariot A. Deregulated NF-kB activity in haematological malignancies. Biochem Pharmacol. 2006;72:1069–80.CrossRefPubMed
19.
Zurück zum Zitat Tidow N, Chen X, Muller C, Kawano S, Gombart AF, Fischel-Ghodsian N, et al. Hematopoietic-specific expression of MEFV, the gene mutated in familial Mediterranean fever, and subcellular localization of its corresponding protein, pyrin. Blood. 2000;95:1451–5.PubMed Tidow N, Chen X, Muller C, Kawano S, Gombart AF, Fischel-Ghodsian N, et al. Hematopoietic-specific expression of MEFV, the gene mutated in familial Mediterranean fever, and subcellular localization of its corresponding protein, pyrin. Blood. 2000;95:1451–5.PubMed
20.
Zurück zum Zitat Sasaki K, Tahara T, Mitani K. Presentation of familial Mediterranean fever in a heterozygous MEFV mutation triggered by immunosuppressive therapy for myelodysplastic syndrome. Int J Hematol. 2009;90:91–3.CrossRefPubMed Sasaki K, Tahara T, Mitani K. Presentation of familial Mediterranean fever in a heterozygous MEFV mutation triggered by immunosuppressive therapy for myelodysplastic syndrome. Int J Hematol. 2009;90:91–3.CrossRefPubMed
21.
Zurück zum Zitat Miyoshi T, Yamashita K, Ohno T, Izumi T, Takaori-Kondo A, Sasada M, et al. Familial Mediterranean fever gene as a possible modifier of sweet syndrome with chronic myelogenous leukemia. Acta Haematol. 2008;120:57–62.CrossRefPubMed Miyoshi T, Yamashita K, Ohno T, Izumi T, Takaori-Kondo A, Sasada M, et al. Familial Mediterranean fever gene as a possible modifier of sweet syndrome with chronic myelogenous leukemia. Acta Haematol. 2008;120:57–62.CrossRefPubMed
22.
Zurück zum Zitat Kotone-Miyahara Y, Takaori-Kondo A, Fukunaga K, Goto M, Hayashino Y, Miki M, et al. E148Q/M694I mutation in 3 Japanese patients with familial Mediterranean fever. Int J Hematol. 2004;79:235–7.CrossRefPubMed Kotone-Miyahara Y, Takaori-Kondo A, Fukunaga K, Goto M, Hayashino Y, Miki M, et al. E148Q/M694I mutation in 3 Japanese patients with familial Mediterranean fever. Int J Hematol. 2004;79:235–7.CrossRefPubMed
23.
Zurück zum Zitat Demirkaya E, Tunca Y, Gok F, Ozen S, Gul D. A very frequent mutation and remarkable association of R761H with M694V mutations in Turkish familial Mediterranean fever patients. Clin Rheumatol. 2008;27:729–32.CrossRefPubMed Demirkaya E, Tunca Y, Gok F, Ozen S, Gul D. A very frequent mutation and remarkable association of R761H with M694V mutations in Turkish familial Mediterranean fever patients. Clin Rheumatol. 2008;27:729–32.CrossRefPubMed
24.
Zurück zum Zitat Yilmaz E, Ozen S, Balci B, Duzova A, Topaloglu R, Besbas N, et al. Mutation frequency of familial Mediterranean fever and evidence for a high carrier rate in the Turkish population. Eur J Hum Genet. 2001;9:553–5.CrossRefPubMed Yilmaz E, Ozen S, Balci B, Duzova A, Topaloglu R, Besbas N, et al. Mutation frequency of familial Mediterranean fever and evidence for a high carrier rate in the Turkish population. Eur J Hum Genet. 2001;9:553–5.CrossRefPubMed
25.
Zurück zum Zitat Apte RN, Dotan S, Elkabets M, White MR, Reich E, Carmi Y, et al. The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor–host interactions. Cancer Metastasis Rev. 2006;25:387–408.CrossRefPubMed Apte RN, Dotan S, Elkabets M, White MR, Reich E, Carmi Y, et al. The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor–host interactions. Cancer Metastasis Rev. 2006;25:387–408.CrossRefPubMed
26.
Zurück zum Zitat Apte RN, Voronov E. Is interleukin-1 a good or bad ‘guy’ in tumor immunobiology and immunotherapy? Immunol Rev. 2008;222:222–41.CrossRefPubMed Apte RN, Voronov E. Is interleukin-1 a good or bad ‘guy’ in tumor immunobiology and immunotherapy? Immunol Rev. 2008;222:222–41.CrossRefPubMed
27.
Zurück zum Zitat Cilloni D, Martinelli G, Messa F, Baccarani M, Saglio G. Nuclear factor κB as a target for new drug development in myeloid malignancies. Haematologica. 2007;92:1124–9.CrossRef Cilloni D, Martinelli G, Messa F, Baccarani M, Saglio G. Nuclear factor κB as a target for new drug development in myeloid malignancies. Haematologica. 2007;92:1124–9.CrossRef
28.
Zurück zum Zitat Ghosh S, May MJ, Kopp EB. NF-kappaB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol. 1998;16:225–60.CrossRefPubMed Ghosh S, May MJ, Kopp EB. NF-kappaB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol. 1998;16:225–60.CrossRefPubMed
29.
Zurück zum Zitat Biswas SK, Gangi L, Paul S, Schioppa T, Saccani A, Sironi M, et al. A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood. 2006;107:2112–22.CrossRefPubMed Biswas SK, Gangi L, Paul S, Schioppa T, Saccani A, Sironi M, et al. A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood. 2006;107:2112–22.CrossRefPubMed
30.
Zurück zum Zitat Kerbauy DB, Deeg HJ. Apoptosis and antiapoptotic mechanisms in the progression of myelodysplastic syndrome. Exp Hematol. 2007;35:1739–46.CrossRefPubMed Kerbauy DB, Deeg HJ. Apoptosis and antiapoptotic mechanisms in the progression of myelodysplastic syndrome. Exp Hematol. 2007;35:1739–46.CrossRefPubMed
31.
Zurück zum Zitat Bouscary D, De Vos J, Guesnu M, Jondeau K, Viguier F, Melle J, et al. Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes. Leukemia. 1997;11:839–45.CrossRefPubMed Bouscary D, De Vos J, Guesnu M, Jondeau K, Viguier F, Melle J, et al. Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes. Leukemia. 1997;11:839–45.CrossRefPubMed
32.
Zurück zum Zitat Zang DY, Goodwin RG, Loken MR, Bryant E, Deeg HJ. Expression of tumor necrosis factor-related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on in vitro hemopoiesis. Blood. 2001;98:3058–65.CrossRefPubMed Zang DY, Goodwin RG, Loken MR, Bryant E, Deeg HJ. Expression of tumor necrosis factor-related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on in vitro hemopoiesis. Blood. 2001;98:3058–65.CrossRefPubMed
33.
Zurück zum Zitat Kerbauy DM, Lesnikov V, Abbasi N, Seal S, Scott B, Deeg HJ. NF-κB and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs). Blood. 2005;106:3917–25.CrossRefPubMed Kerbauy DM, Lesnikov V, Abbasi N, Seal S, Scott B, Deeg HJ. NF-κB and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs). Blood. 2005;106:3917–25.CrossRefPubMed
34.
Zurück zum Zitat Braun T, Carvalho G, Fabre C, Grosjean J, Fenaux P, Kroemer G. Targeting NF-κB in hematologic malignancies. Cell Death Differ. 2006;13:748–58.CrossRefPubMed Braun T, Carvalho G, Fabre C, Grosjean J, Fenaux P, Kroemer G. Targeting NF-κB in hematologic malignancies. Cell Death Differ. 2006;13:748–58.CrossRefPubMed
35.
Zurück zum Zitat Frelin C, Imbert V, Griessinger E, Peyron AC, Rochet N, Philip P, et al. Targeting NF-κB activation via pharmacologic inhibition of IKK2 induced apoptosis of human acute myeloid leukaemia cells. Blood. 2005;105:804–11.CrossRefPubMed Frelin C, Imbert V, Griessinger E, Peyron AC, Rochet N, Philip P, et al. Targeting NF-κB activation via pharmacologic inhibition of IKK2 induced apoptosis of human acute myeloid leukaemia cells. Blood. 2005;105:804–11.CrossRefPubMed
36.
Zurück zum Zitat Guzman ML, Neering SJ, Upchurch D, Grimes B, Howard DS, Rizzieri DA, et al. Nuclear factor-κB is constitutively activated in primitive human acute myelogenous leukaemia cells. Blood. 2001;98:2301–7.CrossRefPubMed Guzman ML, Neering SJ, Upchurch D, Grimes B, Howard DS, Rizzieri DA, et al. Nuclear factor-κB is constitutively activated in primitive human acute myelogenous leukaemia cells. Blood. 2001;98:2301–7.CrossRefPubMed
37.
Zurück zum Zitat Baumgartner B, Weber M, Quirling M, Fischer C, Page S, Adam M, et al. Increased IkappaB kinase activity is associated with activated NF-kappaB in acute myeloid blasts. Leukemia. 2002;16:2062–71.CrossRefPubMed Baumgartner B, Weber M, Quirling M, Fischer C, Page S, Adam M, et al. Increased IkappaB kinase activity is associated with activated NF-kappaB in acute myeloid blasts. Leukemia. 2002;16:2062–71.CrossRefPubMed
38.
Zurück zum Zitat Bueso-Ramos CE, Rocha FC, Shishodia S, Medeiros LJ, Kantarjian HM, Vadhan-Raj S, et al. Expression of constitutively active nuclear-kB RelA transcription factor in blasts of acute myeloid leukaemia. Hum Pathol. 2003;35:246–53.CrossRef Bueso-Ramos CE, Rocha FC, Shishodia S, Medeiros LJ, Kantarjian HM, Vadhan-Raj S, et al. Expression of constitutively active nuclear-kB RelA transcription factor in blasts of acute myeloid leukaemia. Hum Pathol. 2003;35:246–53.CrossRef
39.
Zurück zum Zitat Reuther JY, Reuther GW, Cortez D, Pendergast AM, Baldwin AS Jr. A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation. Genes Dev. 1998;12:968–81.CrossRefPubMed Reuther JY, Reuther GW, Cortez D, Pendergast AM, Baldwin AS Jr. A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation. Genes Dev. 1998;12:968–81.CrossRefPubMed
40.
Zurück zum Zitat Kirchner D, Duyster J, Ottmann O, Schmid RM, Bergmann L, Munzert G. Mechanisms of Bcr-Abl-mediated NF-kappB/Rel activation. Exp Hematol. 2003;31:504–11.CrossRefPubMed Kirchner D, Duyster J, Ottmann O, Schmid RM, Bergmann L, Munzert G. Mechanisms of Bcr-Abl-mediated NF-kappB/Rel activation. Exp Hematol. 2003;31:504–11.CrossRefPubMed
41.
Zurück zum Zitat Grateau G, Pecheux C, Cazeneuve C, Cattan D, Dervichian M, Goossens M, et al. Clinical versus genetic diagnosis of familial Mediterranean fever. Q J Med. 2000;93:223–9. Grateau G, Pecheux C, Cazeneuve C, Cattan D, Dervichian M, Goossens M, et al. Clinical versus genetic diagnosis of familial Mediterranean fever. Q J Med. 2000;93:223–9.
Metadaten
Titel
High frequency of MEFV gene mutations in patients with myeloid neoplasm
verfasst von
Cagatay Oktenli
Ozkan Sayan
Serkan Celik
Alev A. Erikci
Yusuf Tunca
Hakan M. Terekeci
Elcin Erkuvan Umur
Yavuz S. Sanisoglu
Deniz Torun
Fatih Tangi
Burak Sahan
Selim Nalbant
Publikationsdatum
01.06.2010
Verlag
Springer Japan
Erschienen in
International Journal of Hematology / Ausgabe 5/2010
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-010-0577-x

Weitere Artikel der Ausgabe 5/2010

International Journal of Hematology 5/2010 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.